Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Fast And Furious: How The First-To-Market Advantage Is Shrinking

The competitive dynamics in the pharmaceutical sector appear to be intensifying, with second- and third-to-market drugs reaching the market faster behind first-in-class drugs. That's putting more pressure on new drug launches and impacting drug pricing and rebating strategies.

Launches Market Access Pricing Strategies

Spotlight On Israel: Market Challenges Stunting Biopharma Growth

Scrip investigates the big issues Israel's biopharma sector need to overcome in order to maintain momentum and achieve sustainable success.

Israel Market Intelligence Financing

Sweet Enough? Takeda Raises, Adds Cash To Shire Offer

Takeda has further bumped up its offer for acquisition target Shire, raising the per share price and cash component, in what the Japanese firm says is a “compelling” proposal worth well over $60bn. Will it be fourth time lucky?

Japan Commercial M & A
Advertisement


 Recent Tweets from Scrip


 

Commercial Explore this Topic

Set Alert for Commercial

Stock Scan Q1 2018: A Slump And A Proper Correction

The story of the first quarter of 2018 is the impact of the general stock downturn at the end of January and the selective recovery that followed. But even though AbbVie and others had their own private yo-yos, the real correction took a while.

Sales & Earnings Companies Financing

Pharma Q1 Results Preview: Lilly, Biogen, Amgen, GSK & Roche

Investors await news from Lilly on whether it will use repatriated cash for M&A; from Biogen on its Spinraza and gene therapy strategies in light of Novartis' AveXis deal; and from Amgen on pipeline programs and acquisitions as major products face new competition. Immuno-oncology combination updates are anticipated from Roche, plus guidance on how GSK will cope with Advair generics, HIV competition from Gilead and the cost of new drug launches is expected.

Sales & Earnings Business Strategies Commercial

Oncology Venture Differentiates Using Big Data Systems Biology

With six oncology assets in Phase II/III ready for outlicensing, Oncology Venture is now looking to take additional programs on board.

Business Strategies Financing

Deal Watch: Fresenius Drops Bid For Akorn, Citing Data-Integrity Concerns

Janssen and Bristol team to develop next-generation oral anticoagulant, while UCB buys Proximagen's nasal spray candidate and Duke spinout focused on genomics.
Business Strategies Deals

Win-Win For Alnylam And Dicerna With RNAi Trade Secrets Settlement

Although Dicerna needs to make some payments to Alnylam to settle a patent infringement case, the company has avoided an expensive court trial and is free to find partners for its early-stage RNAi therapeutics programs.

Intellectual Property Rare Diseases

AstraZeneca Seeks To Ward Off Brilinta Patent Infringer In India

An Indian court has blocked an alleged infringer of AstraZeneca's patent pertaining to Brilinta (ticagrelor), but the case, some experts claim, also brings to the fore certain controversial tactics at play in the legal arena as large firms pursue litigation to safeguard their intellectual property.

Commercial Strategy

ADAPT Or Die: Argos Therapeutics On Brink After Phase III Failure

The US firm brings in advisors as it considers its options after the Phase III ADAPT study of its cancer immunotherapy fails even after change to protocol.

Companies Clinical Trials

New Active Substance First Launches Rebound In 2017

2017 was the second-best year for new drug launches worldwide since the start of the millennium, new research by Informa Pharma Intelligence's Pharmaprojects has found.

Approvals Commercial

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Lilly May Need To Reassess Baricitinib Market After FDA Advisory Committee

During a mixed review by the US FDA's Arthritis Advisory Committee, panelists suggested that risks potentially associated with Lilly/Incyte's JAK inhibitor would be acceptable for a more limited patient population.

Advisory Committees Drug Safety Inflammation

China Vs Cancer: An Infographic Snapshot

Cancer cases are rising in China, with larger increases for certain types including thyroid and pancreatic. To combat the rising tide, the government will implement zero tariffs on imported anticancer drugs  from May.

Cancer China

Modus CEO Says Rare Disease Priority Review Voucher To Be Key Catalyst

The US FDA gives Sweden's privately held Modus Therapeutics rare pediatric disease designation for sickle cell disease.

Business Strategies Companies

India Leads Global 65% Surge In Antibiotics Use

Human antibiotic consumption globally jumped dramatically between 2000 and 2015, with India posting the biggest rise, reports a new US study, which calls for a radical policy rethink to prevent antimicrobial drug resistance soaring.

India Policy & Regulation

Research & Development Explore this Topic

Set Alert for Research & Development

Synthetic Biologics’ Ribaxamase Setback Shows Difficulty Of C. Difficile Development

Company believes there is a path forward for developing ribaxamase in Phase III, based on discussions with the FDA, but deaths in Phase II meant loss of breakthrough designation.

Clinical Trials Drug Approval Standards FDA

Glenmark Eyes Blockbuster Status For First In-House Biologic

Indian drug firm Glenmark Pharmaceuticals says it’s launching a Phase 2b clinical trial for its first biologic developed in-house, a medicine to treat atopic dermatitis that the company believes may have blockbuster potential.

Research & Development Clinical Trials

ADAPT Or Die: Argos Therapeutics On Brink After Phase III Failure

The US firm brings in advisors as it considers its options after the Phase III ADAPT study of its cancer immunotherapy fails even after change to protocol.

Companies Clinical Trials

Next-Generation CAR-Ts Tackle First-Generation Safety, Solid Tumor Challenges

New strategies to overcome safety, solid tumor and other challenges associated with CAR-T therapies – and some early clinical data for patients treated with Poseida's, Celyad's and Autolus' novel products – were featured at the American Association for Cancer Research (AACR) meeting.

Clinical Trials ImmunoOncology
UsernamePublicRestriction

Register

Advertisement